7AA Preclinical Only
ABP-7
A 7-amino acid actin-binding fragment of Thymosin Beta-4; preclinical evidence for wound repair and angiogenesis, no human trials, no independent neuromodulatory data.
In Plain English:
ABP-7 is a synthetic heptapeptide corresponding to residues 17-23 of Thymosin Beta-4 (the same active domain marketed as TB-500). It mimics the actin-sequestering core of TB4: by binding free (G-actin) monomers it loosens cytoskeletal tension at cell edges, enabling keratinocytes, endothelial cells, and fibroblasts to migrate into wound beds. Several peer-reviewed rodent studies confirm its wound-healing activity is comparable to the full 43-amino-acid parent molecule. Neuromodulatory claims circulating in vendor copy have no primary-source support as of 2026-05-04.
Research Maturity
Preclinical Only (No papers under 'ABP-7'; parent fragment Ac-LKKTETQ in ~6 publications (2003-2020), all animal/in vitro+ Studies)
Focus
Mood & Cognition
Stress Response
Origin
Synthetic fragment of human Thymosin Beta-4 (amino acids 17-23); also the active core of the veterinary product TB-500.
Mechanism
Sequesters G-actin monomers, suppressing F-actin polymerization globally while releasing local G-actin at the leading edge to permit directional cell migration. Downstream: promotes VEGF-driven endothelial sprouting at ~50 nM; blocks Akt phosphorylation (T308/S473) in hepatic stellate cells via PDGF-BB pathway inhibition; may modulate Toll-like receptor adaptor proteins IRAK1/TRAF6 through cortical actin dynamics.
Outcome
Keratinocyte/endothelial/fibroblast migration, dermal wound closure, angiogenesis, collagen deposition, anti-fibrotic signaling in vitro.
